$39.22▾ 3.11%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$0.25cash per $1 profit
Weak
Much of its reported profit is not backed by operating cash.
Valuation
29th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
-22.6%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Rigel Pharmaceuticals, Inc. turns 25¢ of every reported profit-dollar into real cash. Much of its reported profit is not backed by operating cash. Revenue is contracting year over year. Its valuation sits in the cheaper end of its own recent range.
Key numbers
Valuation
EPS (TTM)$16.88
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin116.3%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$276.79M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.